NeurAxis, Inc.
$7
▲
0.97%
2026-04-21 08:28:01
neuraxis.com
ASE: NRXS
Explore NeurAxis, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$80.77 M
Current Price
$7
52W High / Low
$7.97 / $1.33
Stock P/E
—
Book Value
$0.32
Dividend Yield
—
ROCE
-216.78%
ROE
-2.85%
Face Value
—
EPS
$-0.95
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
24
Beta
1.89
Debt / Equity
12.55
Current Ratio
2.05
Quick Ratio
1.96
Forward P/E
-342
Price / Sales
21.44
Enterprise Value
$71.99 M
EV / EBITDA
-10.08
EV / Revenue
20.17
Rating
None
Target Price
$11
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Genelux Corporation | $2.65 | — | $125.01 M | — | -259.44% | -1.7% | $8.54 / $2.25 | $0.31 |
| 2. | Xeris Biopharma Holdings, Inc. | $6.25 | 1,885.02 | $1.04 B | — | 9.09% | -6.96% | $10.08 / $3.95 | $0.08 |
| 3. | Whitehawk Therapeutics, Inc. | $4.23 | — | $193.98 M | — | -83.93% | -21.82% | $4.48 / $1.39 | $2.89 |
| 4. | Immuneering Corporation | $5.53 | — | $359.47 M | — | -26.76% | -43.12% | $10.08 / $1.1 | $3.38 |
| 5. | Catalyst Pharmaceuticals, Inc. | $26.07 | 14.85 | $3.18 B | — | 26.94% | 25.49% | $26.58 / $19.05 | $7.79 |
| 6. | Phio Pharmaceuticals Corp. | $1.27 | — | $14.75 M | — | -45.76% | -69.95% | $4.19 / $0.81 | $1.73 |
| 7. | GridAI Technologies Corp. | $2.79 | — | $9.38 M | — | -27% | -58.82% | $5.84 / $0.97 | — |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.97 M | 0.81 M | 0.89 M | 0.9 M | 0.76 M | — |
| Operating Profit | -1.72 M | -2.1 M | -1.72 M | -2.3 M | -1.47 M | — |
| Net Profit | -1.71 M | -2.12 M | -1.69 M | -2.28 M | -1.45 M | — |
| EPS in Rs | -0.15 | -0.19 | -0.15 | -0.2 | -0.13 | -0.25 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 3.57 M | 2.69 M | 2.46 M | 2.68 M |
| Operating Profit | -7.83 M | -7.16 M | -6.66 M | -3.37 M |
| Net Profit | -7.8 M | -8.24 M | -14.63 M | -4.78 M |
| EPS in Rs | -0.7 | -0.74 | -1.31 | -0.43 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 6.4 M | 4.76 M | 0.51 M | 1.48 M |
| Total Liabilities | 3 M | 2.69 M | 1.91 M | 7.05 M |
| Equity | 3.4 M | 2.07 M | -1.4 M | -5.57 M |
| Current Assets | 5.73 M | 4.27 M | 0.24 M | 0.48 M |
| Current Liabilities | 2.79 M | 2.43 M | 1.89 M | 6.98 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -6.43 M | -6.1 M | -6.69 M | -2.3 M |
| Investing CF | -0.13 M | -0.03 M | -0.07 M | -0.06 M |
| Financing CF | 7.83 M | 9.74 M | 6.59 M | 2.29 M |
| Free CF | -6.56 M | -6.13 M | -6.77 M | -2.36 M |
| Capex | -0.13 M | -0.03 M | -0.07 M | -0.06 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 9.18% | -8.37% | — | — |
| Earnings Growth % | 43.65% | -205.99% | — | — |
| Profit Margin % | -306.84% | -594.57% | -178.05% | — |
| Operating Margin % | -266.46% | -270.91% | -125.61% | — |
| Gross Margin % | 86.52% | 87.67% | 88.94% | — |
| EBITDA Margin % | -294.24% | -375.11% | -161.11% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.